Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Westin

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Advances in Radiation Oncology|November 9, 2017
Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisionsChelsea C Pinnix, Therese Y Andraos, Bouthaina Dabaja, et al.
British Journal of Haematology|May 23, 2018
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)Preetesh Jain, Jorge Romaguera, Samer A Srour, et al.
Cancer|April 16, 2026
Assessing patient perspectives on enrollment in lymphoma clinical trialsNeha Akkad, Minxing Chen, Sophia Nguyen, et al.
Blood|September 15, 2020
Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphomaPaolo Strati, Preetesh Jain, Ralph J Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics|February 16, 2019
Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) LymphomaChelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, et al.
Oncotarget|February 9, 2018
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphomaWei Liu, Juan Chen, Archito T Tamayo, et al.
The American Journal of Surgical Pathology|August 18, 2017
Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal CenterXin Li, Zijun Y Xu-Monette, Shuhua Yi, et al.
Blood Advances|April 12, 2024
Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHLChijioke Nze, Clark R Andersen, Amy A Ayers, et al.
The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2017
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOPPaolo Strati, Nathan Fowler, Sergio Pina-Oviedo, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Advances in Radiation Oncology|November 9, 2017
Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisionsChelsea C Pinnix, Therese Y Andraos, Bouthaina Dabaja, et al.
British Journal of Haematology|May 23, 2018
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)Preetesh Jain, Jorge Romaguera, Samer A Srour, et al.
Cancer|April 16, 2026
Assessing patient perspectives on enrollment in lymphoma clinical trialsNeha Akkad, Minxing Chen, Sophia Nguyen, et al.
Blood|September 15, 2020
Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphomaPaolo Strati, Preetesh Jain, Ralph J Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics|February 16, 2019
Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) LymphomaChelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, et al.
Oncotarget|February 9, 2018
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphomaWei Liu, Juan Chen, Archito T Tamayo, et al.
The American Journal of Surgical Pathology|August 18, 2017
Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal CenterXin Li, Zijun Y Xu-Monette, Shuhua Yi, et al.
Blood Advances|April 12, 2024
Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHLChijioke Nze, Clark R Andersen, Amy A Ayers, et al.
The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2017
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOPPaolo Strati, Nathan Fowler, Sergio Pina-Oviedo, et al.
Pageof 10